Yale School of Medicine: Researchers Find a Vulnerability in Lung Cancers Resistant to Targeted Therapies
August 04, 2023
August 04, 2023
NEW HAVEN, Connecticut, Aug. 4 (TNSres) -- The Yale University School of Medicine issued the following news:
* * *
The study uncovers the role for BAF complexes in mediating resistance to osimertinib and other tyrosine kinase inhibitors
* * *
Targeted therapies have revolutionized cancer treatment and the field of oncology. The FDA has approved over 70 targeted therapies for various cancer types, including lung cancer. Epidermal growth factor r . . .
* * *
The study uncovers the role for BAF complexes in mediating resistance to osimertinib and other tyrosine kinase inhibitors
* * *
Targeted therapies have revolutionized cancer treatment and the field of oncology. The FDA has approved over 70 targeted therapies for various cancer types, including lung cancer. Epidermal growth factor r . . .